Parkinson’s Disease Market Landscape 2032: Epidemiological Trends, Treatment Innovations, Clinical Trial, and Market Growth by DelveInsight | Cerevel Therapeutics, Roche, Pfizer, Biogen, AbbVie, etc

“Parkinson’s Disease Market”
Key companies working in the Parkinson’s Disease Market are Cerevel Therapeutics, Roche, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, Annovis Bio, Amneal Pharmaceuticals, BioVie, Cerevance, Clene Nanomedicine, Intra-Cellular Therapies, Prothena Corporation, and others.

(Albany, USA) The report “Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast-2032” by DelveInsight provides a comprehensive understanding of Parkinson’s disease, including its historical and projected epidemiology. The report also analyzes market trends for Parkinson’s disease in the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan, offering valuable insights into this market.

The report on the Parkinson’s disease market presents up-to-date information on treatment methods, newly developed drugs, the market share of various therapies, and the current and projected size of the Parkinson’s disease market from 2019 to 2032, divided into seven major markets. It also includes details about the current treatment practices and algorithms for managing Parkinson’s disease, along with an analysis of the factors driving the market, barriers faced, and unmet medical needs. By examining these aspects, the report aims to identify the most promising opportunities and evaluate the underlying potential of the Parkinson’s disease market.


Request for a Free Sample Report @ Parkinson’s disease market forecast


Some facts of the Parkinson’s disease Market Report are:

  • According to DelveInsight, Parkinson’s disease market is expected to grow at a decent CAGR by 2032.
  • As per DelveInsight analysis, the Parkinson’s disease market size in the 7MM was approximately USD 3.2 billion in 2022.
  • Leading Parkinson’s disease companies working in the market are Cerevel Therapeutics, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, Annovis Bio, Amneal Pharmaceuticals, BioVie, Cerevance, Clene Nanomedicine, Intra-Cellular Therapies, Hoffmann-La Roche, Prothena Corporation, and others
  • Key Parkinson’s disease Therapies expected to launch in the market are Tavapadon, P2B001, ABBV-951 (foscarbidopa/foslevodopa), BIIB122/DNL151, Buntanetap, IPX203, NE3107, CVN424, CNM-Au8, ITI-214 (lenrispodun), Prasinezumab (RO7046015/RG7935/PRX002), and others.


Parkinson’s disease Overview

Parkinson’s disease is a progressive neurological disorder that affects movement and coordination. It is caused by the degeneration of dopamine-producing neurons in the brain, primarily in an area called the substantia nigra. The loss of dopamine leads to the characteristic motor symptoms of Parkinson’s disease, such as tremors, rigidity, bradykinesia (slowness of movement), and postural instability.

Apart from motor symptoms, individuals with Parkinson’s disease may also experience non-motor symptoms such as depression, anxiety, sleep disturbances, and cognitive impairments. The exact cause of Parkinson’s disease is still not fully understood, but both genetic and environmental factors are believed to play a role.

Currently, there is no cure for Parkinson’s disease, but various treatment options are available to manage symptoms and improve quality of life. Medications such as levodopa and dopamine agonists are commonly prescribed to increase dopamine levels in the brain. Other treatments include deep brain stimulation, physical therapy, occupational therapy, and speech therapy.


Learn more about Parkinson’s disease treatment algorithms in different geographies, and patient journeys. Request for a Free Sample Report @


Parkinson’s disease Market

The Parkinson’s disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Parkinson’s disease market trends by analyzing the impact of current Parkinson’s disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Parkinson’s disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Parkinson’s disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Parkinson’s disease market in 7MM is expected to witness a major change in the study period 2019-2032.


Parkinson’s disease Epidemiology

The Parkinson’s disease epidemiology section provides insights into the historical and current Parkinson’s disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Parkinson’s disease market report also provides the diagnosed patient pool, trends, and assumptions. 


Parkinson’s disease Epidemiology Segmentation

  • Parkinson’s Disease Diagnosed Prevalent Population
  • Parkinson’s Disease Gender-specific Diagnosed Prevalent Population
  • Parkinson’s Disease Age-specific Diagnosed Prevalent Population
  • Parkinson’s Disease Stage-specific Diagnosed Prevalent Population

Request for a Free Sample Report @


Parkinson’s disease Drugs Uptake

This section focuses on the uptake rate of the potential Parkinson’s disease drugs recently launched in the Parkinson’s disease market or expected to be launched in 2019-2032. The analysis covers the Parkinson’s disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Parkinson’s disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Parkinson’s disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Parkinson’s disease Pipeline Development Activities

The Parkinson’s disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Parkinson’s disease key players involved in developing targeted therapeutics.

  • Tavapadon: Cerevel Therapeutics/Pfizer
  • P2B001: Pharma Two B
  • ABBV-951 (foscarbidopa/foslevodopa): AbbVie
  • BIIB122/DNL151: Biogen/Denali Therapeutics
  • Buntanetap: Annovis Bio
  • IPX203: Amneal Pharmaceuticals
  • NE3107: BioVie
  • CVN424: Cerevance
  • CNM-Au8: Clene Nanomedicine
  • ITI-214 (lenrispodun): Intra-Cellular Therapies
  • Prasinezumab (RO7046015/RG7935/PRX002): Hoffmann-La Roche/Prothena Corporation


Request for a sample report to understand more about the Parkinson’s disease pipeline development activities. Request for a Free Sample Report @


Parkinson’s disease Therapeutics Assessment

Prominent companies are actively engaged in the Parkinson’s disease Therapeutics market, taking proactive measures to develop innovative therapies that will propel the growth of the Parkinson’s disease treatment sector in the coming years. These companies include Cerevel Therapeutics, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, Annovis Bio, Amneal Pharmaceuticals, BioVie, Cerevance, Clene Nanomedicine, Intra-Cellular Therapies, Hoffmann-La Roche, Prothena Corporation, and others.


Learn more about the emerging Parkinson’s disease therapies & key companies @


Parkinson’s disease Market Report Key Insights

1. Parkinson’s disease Patient Population

2. Parkinson’s disease Market Size and Trends

3. Key Cross Competition in the Parkinson’s disease Market

4. Parkinson’s disease Market Dynamics (Key Drivers and Barriers)

5. Parkinson’s disease Market Opportunities

6. Parkinson’s disease Therapeutic Approaches

7. Parkinson’s disease Pipeline Analysis

8. Parkinson’s disease Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Parkinson’s disease Market


Table of Contents

1. Key Insights

2. Executive Summary

3. Parkinson’s disease Competitive Intelligence Analysis

4. Parkinson’s disease Market Overview at a Glance

5. Parkinson’s disease Disease Background and Overview

6. Parkinson’s disease Patient Journey

7. Parkinson’s disease Epidemiology and Patient Population

8. Parkinson’s disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Parkinson’s disease Unmet Needs

10. Key Endpoints of Parkinson’s disease Treatment

11. Parkinson’s disease Marketed Products

12. Parkinson’s disease Emerging Therapies

13. Parkinson’s disease Seven Major Market Analysis

14. Attribute Analysis

15. Parkinson’s disease Market Outlook (7 major markets)

16. Parkinson’s disease Access and Reimbursement Overview

17. KOL Views on the Parkinson’s disease Market

18. Parkinson’s disease Market Drivers

19. Parkinson’s disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States